Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 108 | 3,119 | 47% |
| 2020 | 83 | 2,781 | 49% |
| 2021 | 108 | 3,641 | 51% |
| 2022 | 127 | 4,135 | 53% |
| 2023 | 134 | 4,445 | 56% |
| 2024 | 139 | 4,787 | 58% |
| 2025 from claims | – | 5,101 4,681–5,397 | 59% |
| 2026 forecast | – | 5,566 4,897–6,423 | 59% |
| 2027 forecast | – | 6,003 5,132–7,154 | 59% |
| 2028 forecast | – | 6,474 5,402–7,927 | 60% |
| 2029 forecast | – | 6,980 5,701–8,754 | 60% |
| 2030 forecast | – | 7,525 6,028–9,643 | 61% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 26% of the cases CMS names in Pennsylvania; 83 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 44% inpatient hospital, 42% hospital outpatient, 4% surgery center, 10% office. The share outside the hospital has moved +5 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~5,600 | ~2,500 | ~2,300 | ~230 | ~530 |
| 2027 · ~6,000 | ~2,700 | ~2,500 | ~250 | ~560 |
| 2028 · ~6,500 | ~2,900 | ~2,700 | ~270 | ~600 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 45% (44% in 2025), hospital outpatient about 41% (42% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 191 | 8,988+5.9%/yr | +5.9%/yr | 4.3 | 12% | 14,400 in 2030+8.1%/yr |
| New Jersey | 90 | 3,940+7.1%/yr | +7.1%/yr | 3.4 | 37% | 6,480 in 2030+8.7%/yr |
| Massachusetts | 67 | 2,548+8.4%/yr | +8.4%/yr | 2.4 | 8% | 4,890 in 2030+11%/yr |
| Connecticut | 35 | 1,043+11%/yr | +11%/yr | 2.7 | 5% | 1,680 in 2030+8.2%/yr |
| New Hampshire | 16 | 537+13%/yr | +13%/yr | 2.1 | 11% | 1,450 in 2030+18%/yr |
| Maine | 13 | 319+15%/yr | +15%/yr | 1.7 | 0% | 450 in 2030+5.7%/yr |
| Rhode Island | 5 | 246−0.3%/yr | −0.3%/yr | 2.3 | 0% | 350 in 2030+6.1%/yr |
| Vermont | 3 | 103−6.7%/yr | −6.7%/yr | 0.8 | 0% | 200 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 147 | 7,396−2.8%/yr | −2.8%/yr | 5.61.2× | 2% | 6,810 in 2030−1.4%/yr |
| EP ablation | 131 | 5,803+11%/yr | +11%/yr | 3.51.1× | 0% | 11,400 in 2030+12%/yr |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Boston Scientific leads with 87% of company spending on these surgeons in 2025, +1 pts on 2024.
In 2025, 4 companies reported engagement with Pennsylvania’s surgeons worth $239K in consulting, speaking, meals and travel tied to these products, about $1,718 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.